In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project summary: Our laboratory invented a novel precision medicine approach for autoimmune disease treatment known as chimeric autoantibody receptor T cell (CAART) therapy, which aims to eliminate only the disease-causing autoimmune B cells while sparing healthy B cells, thus avoiding the risks of general immune suppression. We established initial efficacy of the approach in experimental autoimmune disease models and subsequently initiated a first-in-human clinical trial of DSG3-CAART in mucosal-dominant pemphigus vulgaris, a potentially fatal blistering disease caused by autoantibodies to the epithelial adhesion protein desmoglein 3 (DSG3), and more recently, MuSK-CAART in muscle-specific tyrosine kinase (MuSK) myasthenia gravis, in which autoantibodies to MuSK cause muscle weakness and potentially life-threatening respiratory crisis. DSG3- CAART was generally well-tolerated, although no consistent pattern of clinical or serologic improvement was observed. In contrast, 4 of the first 6 MuSK-CAART-treated patients experienced improvement in clinical disease activity scores, associated with MuSK-CAART expansion and persistence, and 2 of 4 subjects in the higher dose cohort experienced serious adverse events related to therapy. DSG3-CAART and MuSK-CAART are the first precision cellular immunotherapies for autoimmunity to enter clinical trials, which presents a unique opportunity to define the effects of these living drugs in human patients. In a separate line of studies we are investigating DSG3-CAART immune profiles; in this proposal, we will define immune profiles before and after infusion to evaluate pathways activated in MuSK-CAART and host immune cells that may identify biomarkers of safety and efficacy. Our studies will elucidate the cellular mechanisms of MuSK-CAART in vivo and may lead to new strategies for engineering the next generation of precision immunotherapies to achieve safe and durable autoimmune disease remission.
Grant Summary
In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $452K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $452K
2028-01-31
- 1Confirm your organization is eligible for In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis: Frequently Asked Questions
Who is eligible for the In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis?
In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis provide?
In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis provides up to $452K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis deadline?
Applications for In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis?
To apply for In vivo profiling of a first-in-human study of chimeric autoantibody receptor T cells for MuSK myasthenia gravis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.